XOMA (NASDAQ:XOMA) Stock Price Crosses Above Two Hundred Day Moving Average – Here’s Why

Shares of XOMA Co. (NASDAQ:XOMA) crossed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $26.54 and traded as high as $30.98. XOMA shares last traded at $30.86, with a volume of 13,013 shares trading hands.

Analysts Set New Price Targets

Several brokerages recently commented on XOMA. StockNews.com upgraded shares of XOMA from a “sell” rating to a “hold” rating in a research report on Wednesday, August 14th. HC Wainwright restated a “buy” rating and issued a $117.00 price target on shares of XOMA in a research report on Wednesday, October 23rd.

XOMA Trading Up 1.6 %

The company has a current ratio of 8.71, a quick ratio of 8.71 and a debt-to-equity ratio of 1.15. The firm has a market cap of $361.19 million, a PE ratio of -12.39 and a beta of 0.90. The company’s 50-day moving average is $28.30 and its 200 day moving average is $26.54.

XOMA (NASDAQ:XOMA) last released its quarterly earnings data on Tuesday, August 13th. The biotechnology company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.26) by ($0.02). The company had revenue of $11.09 million during the quarter, compared to analyst estimates of $8.37 million. XOMA had a negative net margin of 128.59% and a negative return on equity of 24.50%. As a group, sell-side analysts predict that XOMA Co. will post -1.42 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the stock. BNP Paribas Financial Markets increased its stake in XOMA by 55.6% in the 1st quarter. BNP Paribas Financial Markets now owns 3,543 shares of the biotechnology company’s stock valued at $85,000 after buying an additional 1,266 shares during the period. Rhumbline Advisers increased its stake in shares of XOMA by 16.0% during the 2nd quarter. Rhumbline Advisers now owns 9,695 shares of the biotechnology company’s stock worth $230,000 after purchasing an additional 1,334 shares during the last quarter. Bank of New York Mellon Corp increased its stake in shares of XOMA by 3.2% during the 2nd quarter. Bank of New York Mellon Corp now owns 62,656 shares of the biotechnology company’s stock worth $1,484,000 after purchasing an additional 1,968 shares during the last quarter. Price T Rowe Associates Inc. MD acquired a new position in shares of XOMA during the 1st quarter worth $212,000. Finally, Ellsworth Advisors LLC acquired a new position in shares of XOMA during the 3rd quarter worth $516,000. Institutional investors and hedge funds own 95.92% of the company’s stock.

About XOMA

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.